CDH1 and cancer: E-cadherin loss was demonstrated in a variety of cancers, including lobular breast carcinomas [78], gastric adenocarcinoma [81], hepatocellular carcinoma [82], melanoma [83], squamous cell carcinomas of the skin [84], as well as esophagus [85], and head and neck carcinomas [86,87].